X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Nexletol(bempedoic acid) is an adenosine triphosphate-citrate lyase (ACL) inhibitor indicated as an adjunct to diet and statin therapy for the treatment of heart attack, hypercholesterolaemia & cardiovascular diseases.
Lead Product(s): Bempedoic Acid
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Nexletol
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2024
Details:
The collaboration combines Esperion Therapeutics’ first-in-class ATP Citrate Lyase (ACL) inhibitor, NILEMDO (bempedoic acid), with Daiichi Sankyo’s commercial capabilities, as well as synergies with their existing portfolio of cardiovascular medicines.
Lead Product(s): Bempedoic Acid
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Nilemdo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Daiichi Sankyo
Deal Size: $1,255.0 million Upfront Cash: $30.0 million
Deal Type: Collaboration January 03, 2024
Details:
Nexletol (bempedoic acid) is indicated as an adjunct to diet and maximally tolerated statin therapy for treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C.
Lead Product(s): Bempedoic Acid
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Nexletol
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 19, 2022
Details:
NEXLETOL (bempedoic acid) is indicated as an adjunct to diet and maximally tolerated statin therapy for treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C
Lead Product(s): Bempedoic Acid
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Nexletol
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2022
Details:
Esperion intends to use the net proceeds from the offering to fund the ongoing commercialization efforts for NEXLETOL and NEXLIZET, research and clinical development of current or additional pipeline candidates, and general corporate purposes.
Lead Product(s): Bempedoic Acid
Therapeutic Area: Genetic Disease Product Name: Nexletol
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $225.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 02, 2021
Details:
Bempedoic acid is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C.
Lead Product(s): Bempedoic Acid,Ezetimibe
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Nexlizet
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 01, 2021
Details:
The agreement combines Esperion Therapeutics’ first-in-class ATP Citrate Lyase (ACL) inhibitor, bempedoic acid, with Daiichi Sankyo’s commercial capabilities, as well as synergies with their existing portfolio of cardiovascular medicines.
Lead Product(s): Bempedoic Acid,Ezetimibe
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Nexlizet
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Daiichi Sankyo
Deal Size: $1,130.0 million Upfront Cash: $30.0 million
Deal Type: Partnership April 26, 2021
Details:
The aim of this Phase 2 study was to evaluate LDL-C lowering when NEXLETOL was initiated together with ezetimibe (10 mg) and atorvastatin (20 mg), as compared with placebo.
Lead Product(s): Bempedoic Acid,Ezetimibe,Atorvastatin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Nexletol
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 17, 2021
Details:
ESPERION has entered into a definitive agreement with Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Serometrix developed the oral PCSK9 inhibitor program with its proprietary technology to discover drugs for difficult protein targets.
Lead Product(s): Undisclosed
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Serometrix
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 13, 2021
Details:
Both analyses demonstrated significant lowering of low-density lipoprotein cholesterol (LDL-C) by NEXLETOL® (bempedoic acid) Tablets by week 12 in specific subgroups, including people who cannot tolerate statins and females, compared to placebo.
Lead Product(s): Bempedoic Acid
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Nexletol
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 13, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
